

PRODUCT MONOGRAPH

INCLUDING PATIENT MEDICATION INFORMATION



retifanlimab for injection

Concentrate for solution for intravenous infusion

25 mg/mL

Professed Standard

Antineoplastic agent

ATC code: L01FF10

Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
USA
www.incyte.com

Imported by:
Innomar Strategies Inc.
Oakville, ON
L6L 0C4

Submission Control Number: 284125

ZYNYZ and the ZYNYZ logo are registered trademarks of Incyte.

Date of Initial Authorization:
FEB 06, 2025

Indications

Contraindications

Dosage and
administration

Overdosage

Dosage forms,
strengths, composition
and packaging

Warnings and
precautions

Adverse reactions

Drug interactions

Clinical
pharmacology

Storage, stability
and disposal

Pharmaceutical
information

Clinical trials

Microbiology

Non-clinical
Toxicology

Patient medication
information

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

TABLE OF CONTENTS 2

PART I: HEALTH PROFESSIONAL INFORMATION 4

1 INDICATIONS

- 1.1 Pediatrics 4
- 1.2 Geriatrics 4

2 CONTRAINDICATIONS 5

4 DOSAGE AND ADMINISTRATION 6

- 4.1 Dosing Considerations 6
- 4.2 Recommended Dose and Dosage Adjustment 6
- 4.3 Reconstitution 9
- 4.4 Administration 10
- 4.5 Missed Dose 10

5 OVERDOSAGE 11

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING 12

7 WARNINGS AND PRECAUTIONS 13

- 7.1 Special Populations 17
- 7.1.1 Pregnant Women 17
- 7.1.2 Breastfeeding 18
- 7.1.3 Pediatrics 18
- 7.1.4 Geriatrics 18

Indications

Contraindications

Dosage and
administration

Overdosage

Dosage forms,
strengths, composition
and packagingWarnings and
precautions

Adverse reactions

Drug interactions

Clinical
pharmacologyStorage, stability
and disposalPharmaceutical
information

Clinical trials

Microbiology

Non-clinical
ToxicologyPatient medication
information

TABLE OF CONTENTS

| | | |
|--|-----------|--|
| 8 ADVERSE REACTIONS | 19 | Indications |
| 8.1 Adverse Reaction Overview | 19 | |
| 8.2 Clinical Trial Adverse Reactions..... | 20 | Contraindications |
| 8.3 Less Common Clinical Trial Adverse Reactions..... | 25 | |
| 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data..... | 25 | Dosage and administration |
| 9 DRUG INTERACTIONS | 27 | Overdosage |
| 9.2 Drug Interactions Overview | 27 | |
| 10 CLINICAL PHARMACOLOGY | 28 | Dosage forms, strengths, composition and packaging |
| 10.1 Mechanism of Action..... | 28 | |
| 10.2 Pharmacodynamics..... | 28 | Warnings and precautions |
| 10.3 Pharmacokinetics | 28 | |
| 11 STORAGE, STABILITY AND DISPOSAL | 31 | Adverse reactions |
| PART II: SCIENTIFIC INFORMATION..... | 32 | Drug interactions |
| 13 PHARMACEUTICAL INFORMATION..... | 32 | Clinical pharmacology |
| 14 CLINICAL TRIALS | 33 | Storage, stability and disposal |
| 14.1 Clinical Trials by Indication..... | 33 | Pharmaceutical information |
| 14.3 Immunogenicity | 35 | |
| 15 MICROBIOLOGY | 36 | Clinical trials |
| 16 NON-CLINICAL TOXICOLOGY | 37 | Microbiology |
| PATIENT MEDICATION INFORMATION..... | 38 | Non-clinical Toxicology |
| | | Patient medication information |

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

ZYNYZ (retifanlimab for injection), as monotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.

Marketing authorization was based on tumor response and durability of response. An improvement in survival or disease-related symptoms has not yet been established (see 14 CLINICAL TRIALS).

1.1 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (≥ 65 years of age): No overall differences in efficacy were observed between younger patients (< 65 years of age) and elderly patients (≥ 65 years of age). Limited information is available to draw conclusions on any differences in safety between younger and elderly patients (see 7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics).

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

2 CONTRAINDICATIONS

Zynyz is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Administer Zynzyz as an intravenous infusion after dilution (see 4 DOSAGE AND ADMINISTRATION, 4.3 Reconstitution, and 4.4 Administration).

Treatment with Zynzyz should be initiated and supervised by a physician experienced in the treatment of cancer.

4.2 Recommended Dose and Dosage Adjustment

The recommended dose of Zynzyz is 500 mg every 4 weeks administered as an intravenous infusion over 30 minutes. Treatment should continue until disease progression, unacceptable toxicity, or up to 24 months.

No dose reductions are recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability. Recommended modifications to manage adverse reactions are provided in Table 1.

Table 1: Recommended Dosage Modifications for Adverse Reactions

| Adverse Reaction | Severity ^a | Dosage Modification |
|---|--|---|
| Pneumonitis | Grade 2 | Withhold until \leq Grade 1. ^b |
| | Grade 3 or 4 | Permanently discontinue. |
| Colitis | Grade 2 or 3 | Withhold until \leq Grade 1. ^b |
| | Grade 4 | Permanently discontinue. |
| Hepatitis with no tumor involvement of the liver OR Increased total bilirubin | ALT or AST greater than 3 but no more than 8 times the ULN OR Total bilirubin increases to more than 1.5 and up to 3 times ULN | Withhold until \leq Grade 1. ^b |
| | AST or ALT increases to more than 8 times ULN OR Total bilirubin greater than 3 times ULN | Permanently discontinue. |

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Table 1: Recommended Dosage Modifications for Adverse Reactions

| Adverse Reaction | Severity ^a | Dosage Modification |
|---|--|---|
| Hepatitis with tumor involvement of the liver OR Increased total bilirubin | AST or ALT more than 5 and up to 10 times ULN OR Total bilirubin greater than 1.5 but no more than 3 times ULN | Withhold until \leq Grade 1. ^b |
| | ALT or AST increase to more than 10 times ULN OR Total bilirubin greater than 3 times ULN | Permanently discontinue. |
| Endocrinopathies Adrenal insufficiency Hypothyroidism Hyperthyroidism Type 1 diabetes mellitus Hyperglycemia Hypophysitis | Grade 2 adrenal insufficiency | Withhold until \leq Grade 1 or otherwise clinically stable. |
| | Grade 3 or 4 adrenal insufficiency | Withhold until \leq Grade 1. ^b Permanently discontinue for worsening while on adequate hormonal therapy. |
| | Grade 3 or 4 hypothyroidism | Withhold until \leq Grade 1 or is otherwise clinically stable. |
| | Grade 3 or 4 hyperthyroidism | Withhold until \leq Grade 1 or is otherwise clinically stable. |
| | Grade 3 or 4 type 1 diabetes mellitus (or hyperglycemia) | Withhold until \leq Grade 1 or is otherwise clinically stable. |
| | Grade 2 hypophysitis (asymptomatic) | Withhold until \leq Grade 1. May restart after controlled by hormone replacement therapy. |
| | Grade 2 hypophysitis (symptomatic; e.g., headaches, visual disturbances) | Withhold until \leq Grade 1. May restart study drug after controlled with hormone replacement therapy, if indicated and steroid taper is complete. |
| | Grade 3 or 4 hypophysitis (symptomatic) | Withhold until \leq Grade 1. ^b Permanently discontinue for worsening while on adequate hormonal therapy. |
| Nephritis with renal dysfunction | Grade 2 increased blood creatinine | Withhold until \leq Grade 1. ^b |
| | Grade 3 or 4 increased blood creatinine | Permanently discontinue. ^c |

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Table 1: Recommended Dosage Modifications for Adverse Reactions

| Adverse Reaction | Severity ^a | Dosage Modification |
|---|--|---|
| Skin Reactions | Grade 3 or suspected SJS or suspected TEN | Withhold until \leq Grade 1. |
| | Grade 4 or confirmed SJS or confirmed TEN | Permanently discontinue. |
| Myocarditis | Confirmed Grades 2, 3 or 4 | Permanently discontinue. |
| Other immune-mediated adverse reactions (including myositis, encephalitis, demyelinating neuropathy, Guillain-Barré syndrome, sarcoidosis, autoimmune hemolytic anemia, pancreatitis, uveitis, diabetic ketoacidosis, arthralgia) | Grade 3 (symptomatic) | Withhold until \leq Grade 1. ^b |
| | Confirmed Grade 3 and Grade 4 | Permanently discontinue. |
| Persistent Grade 2 or 3 adverse reactions (excluding endocrinopathies) | Grade 2 or 3 adverse reactions \geq 12 weeks after last dose | Permanently discontinue. |
| Recurrent immune-mediated adverse reactions | Recurrent Grade 3 or 4 | Permanently discontinue. |
| | Recurrent Grade 2 pneumonitis | Permanently discontinue. |
| Infusion-related reactions | Grades 1 and 2 | Interrupt or slow the rate of infusion. |
| | Grade 3 ^d or 4 or persistent Grade 2 | Permanently discontinue. |

AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal;

SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis.

a Toxicity graded per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.

b Permanently discontinue once diagnosis is confirmed, or if symptoms have no resolution within 12 weeks of initiating steroids or inability to reduce prednisone to less than 10 mg/day (or equivalent) within 12 weeks of initiating steroids.

c Permanently discontinue only if retifanlimab is directly implicated in renal toxicity.

d Grade 3 infusion-related reactions: if rapidly responsive to symptomatic medication and/or to brief interruption of infusion, retifanlimab does not need to be permanently discontinued.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Pediatrics:

Health Canada has not authorized an indication for pediatric use.

Renal Impairment:

There is insufficient data in patients with severe renal impairment and no data for patients with end-stage renal disease and therefore no dosing recommendation can be made (see 10 CLINICAL PHARMACOLOGY).

Hepatic Impairment:

There are insufficient data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment and therefore no dosing recommendations can be made (see 10 CLINICAL PHARMACOLOGY).

4.3 Reconstitution

Preparation

Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration. Zynzyz is a clear to slightly opalescent, colorless to pale yellow solution, free of visible particles.

Discard the vial if the solution is cloudy, discolored, or visible particles are observed.

Do not shake the vial.

Withdraw 20 mL (500 mg) of Zynzyz concentrate from the vial and discard vial with any unused portion.

Dilute Zynzyz with either sodium chloride 9 mg/mL (0.9%) solution for injection, USP or glucose 50 mg/mL (5%) solution for injection, USP to prepare a diluted solution with a final concentration between 1.4 mg/mL to 10 mg/mL. Use polyvinylchloride (PVC) and di-2-ethylhexyl phthalate (DEHP), polyolefin copolymer, polyolefin with polyamide, or ethylene vinyl acetate infusion bags.

Mix the diluted solution by gentle inversion. Do not shake the infusion bag.

Storage of diluted Zynzyz solution

Once prepared, administer the diluted solution immediately. If not administered immediately, it may be stored temporarily either:

- At room temperature up to 25°C for no more than 8 hours from the time of preparation to the end of the infusion.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

OR

- Under refrigeration at 2°C to 8°C for no more than 24 hours from the time of preparation to the end of the infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration. The diluted solution must be administered within 4 hours (including infusion time) once it is removed from the refrigerator.

Do not freeze or shake diluted solution.

4.4 Administration

Administer ZynyZ by intravenous infusion over 30 minutes through a polyethylene, polyurethane, or polyethersulfone, polyvinylidene fluoride, or cellulose acetate 0.2 micron to 5 micron in-line or add-on filter or 15-micron mesh in-line or add-on filter. ZynyZ is only to be administered by intravenous infusion.

Do not co-administer other drugs through the same infusion line. After each dose, flush the infusion line.

4.5 Missed Dose

If a planned dose of ZynyZ is missed, it should be administered as soon as possible. The schedule of administration should be adjusted to maintain the prescribed dosing interval.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

5 OVERDOSAGE

There is no information on overdosage with Zyny. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.

For management of a suspected drug overdose, contact your regional poison control centre.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

To help ensure the traceability of biologic products, healthcare professionals should record both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

**Table 2: Dosage Forms, Strengths, Composition and
Packaging**

| Route of Administration | Dosage Form/ Strength/Composition | Non-medicinal Ingredients |
|----------------------------|---|--|
| Intravenous infusion | Concentrate for solution for infusion 500 mg/20 mL vial (25 mg/mL) | Glacial acetic acid, polysorbate 80, sodium acetate, sucrose, and water for injection. |

Zynzy is packaged in a carton containing a 20 mL vial with a sterile, clear to slightly opalescent, colorless to pale yellow solution with a pH of 5.1. The solution is free from visible particles. Each mL of solution contains 25 mg of retifanlimab.

| |
|---|
| Indications |
| Contraindications |
| Dosage and administration |
| Overdosage |
| Dosage forms, strengths, composition and packaging |
| Warnings and precautions |
| Adverse reactions |
| Drug interactions |
| Clinical pharmacology |
| Storage, stability and disposal |
| Pharmaceutical information |
| Clinical trials |
| Microbiology |
| Non-clinical Toxicology |
| Patient medication information |

7 WARNINGS AND PRECAUTIONS

General

Treatment with Zynzy should be initiated and supervised by a physician experienced in the treatment of cancer.

Driving and Operating Machinery

Exercise caution when driving or operating a vehicle or potentially dangerous machinery (see 8 ADVERSE REACTIONS).

Immune

Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in patients treated with antibodies blocking the programmed death receptor1/programmed death ligand 1 (PD1/PDL1) pathway, including Zynzy. Immune-mediated adverse reactions can occur in any organ or tissue and may affect more than one body system simultaneously. While immune-mediated adverse reactions usually occur during treatment with PD1/PDL1 blocking antibodies, symptoms can also manifest after discontinuation of PD1/PDL1 blocking antibodies. Important immune-mediated adverse reactions listed in this section are not inclusive of all possible immune-mediated reactions.

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of Zynzy. Patients should be monitored for symptoms and signs of immune-mediated adverse reactions. Blood chemistries, including liver tests and thyroid function tests, should be evaluated at start of treatment and periodically during treatment. For suspected immune-mediated adverse reactions, adequate evaluation including specialty consultation should be ensured to confirm etiology or exclude other causes.

Based on the severity of the adverse reaction, treatment with Zynzy should be withheld or permanently discontinued and corticosteroids (1 to 2 mg/kg/day prednisone or equivalent) or other appropriate therapy administered. Upon improvement to \leq Grade 1, corticosteroid taper should be initiated and continued for at least 1 month. In patients whose immune-mediated adverse reactions cannot be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Treatment with Zynzyz should be permanently discontinued for any Grade 3 immune-mediated adverse reaction that recurs and for any Grade 4 immune-mediated adverse reaction, except for endocrinopathies that are controlled with hormone replacement therapy and unless otherwise specified in Table 1.

Immune-mediated pneumonitis

Pneumonitis has been reported in patients receiving Zynzyz (see 8 ADVERSE REACTIONS). Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other causes excluded. Patients should be managed with Zynzyz treatment modifications and corticosteroids (see Table 1).

Immune-mediated colitis

Immune-mediated colitis has been reported in patients receiving Zynzyz (see 8 ADVERSE REACTIONS). Patients should be monitored for signs and symptoms of colitis and managed with Zynzyz treatment modifications, anti-diarrheal agents, and corticosteroids (see Table 1).

Immune-mediated nephritis

Immune-mediated nephritis has been reported in patients receiving Zynzyz (see 8 ADVERSE REACTIONS). Patients should be monitored for changes in renal function and managed with Zynzyz treatment modifications and corticosteroids (see Table 1).

Immune-mediated hepatitis

Immune-mediated hepatitis has been reported in patients receiving Zynzyz (see 8 ADVERSE REACTIONS). Patients should be monitored for changes in liver function prior to and periodically during treatment and as indicated based on clinical evaluation. Manage patients with Zynzyz treatment modifications and corticosteroids (see Table 1).

Immune-mediated skin reactions

Immune-mediated skin reactions, including toxic epidermal necrolysis, have been reported in patients receiving Zynzyz (see 8 ADVERSE REACTIONS). Patients should be monitored for signs and symptoms of skin reactions. Immune-mediated skin reactions should be managed as recommended in Table 1. Events of Stevens Johnson Syndrome have been reported in patients treated with PD1 inhibitors.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Caution should be used when considering the use of Zynzyz in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune checkpoint inhibitors.

Immune-mediated endocrinopathies

Immune-mediated endocrinopathies, including hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, and diabetic ketoacidosis have been reported in patients receiving Zynzyz (see 8 ADVERSE REACTIONS).

Hypothyroidism and hyperthyroidism

Immune-mediated hypothyroidism and hyperthyroidism (including thyroiditis) have been reported in patients receiving Zynzyz. Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and as indicated based on clinical evaluation. Immune-mediated hypothyroidism and hyperthyroidism (including thyroiditis) should be managed with Zynzyz treatment modifications as recommended in Table 1.

Hypophysitis

Immune-mediated hypophysitis has been observed in patients receiving Zynzyz (see 8 ADVERSE REACTIONS). Patients should be monitored for signs and symptoms of hypophysitis and managed with Zynzyz treatment modifications, corticosteroids, and hormone replacement, as clinically indicated in Table 1.

Adrenal insufficiency

Immune-mediated adrenal insufficiency has been reported in patients receiving Zynzyz. Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed with Zynzyz treatment modifications as recommended in Table 1.

Type 1 Diabetes mellitus

Immune-mediated type 1 diabetes mellitus has been observed in patients treated with PD-1 inhibitors (see 8 ADVERSE REACTIONS). Patients should be monitored for hyperglycaemia and signs and symptoms of diabetes as indicated based on clinical evaluation and managed with oral anti-hyperglycemics or insulin and Zynzyz treatment modifications (see Table 1).

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Other immune-mediated adverse reactions

Clinically significant immune-mediated adverse reactions reported in less than 1% of patients treated with Zynzyz in clinical studies include: uveitis, keratitis, myocarditis, pericarditis, cholangitis, arthritis, myositis, polymyalgia rheumatica, demyelinating polyneuropathy (e.g. Guillain Barré syndrome), pancreatitis, and diabetic ketoacidosis (see 8 ADVERSE REACTIONS).

The following clinically significant, immune-mediated adverse reactions were reported with the use of other PD-1/PD-L1 inhibitors: rhabdomyolysis, encephalitis, meningitis, myelitis, myasthenia gravis, hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, immune thrombocytopenic purpura, and sarcoidosis.

Patients should be monitored for signs and symptoms of immune-mediated adverse reactions and managed with Zynzyz treatment modifications as described in Table 1.

Solid organ transplant rejection

Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Treatment with Zynzyz may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with Zynzyz versus the risk of possible organ rejection should be considered in these patients.

Complications of allogeneic hematopoietic stem cell transplantation

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1-blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GvHD), acute GvHD, chronic GvHD, hepatic veno-occlusive disease after reduced intensity conditioning and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Patients should be closely followed for evidence of transplant-related complications and prompt intervention may be required. Consider the benefit versus risks of treatment with a PD-1/PD-L1-blocking antibody prior to or after an allogeneic HSCT.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Infusion-related reactions

As with any therapeutic protein, Zynzyz can cause infusion-related reactions, some of which may be severe. Patients should be monitored for signs and symptoms of infusion-related reactions. Zynzyz treatment should be interrupted, or the rate of infusion slowed, or treatment should be permanently discontinued based on severity of reaction and the response to treatment (see Table 1). Premedication with an antipyretic and/or an antihistamine should be considered for patients who have had previous clinically significant reactions to infusions of therapeutic proteins (see 8 ADVERSE REACTIONS).

Monitoring and Laboratory Tests

Liver function tests (hepatic transaminase and bilirubin levels), thyroid function tests and serum electrolytes should be monitored at the start of treatment, periodically during treatment and as indicated based on clinical evaluation (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS).

Reproductive Health: Female and Male Potential

Fertility

No clinical data are available on the possible effects of Zynzyz on fertility. Animal reproduction studies to evaluate the effect of Zynzyz on fertility have not been conducted. No effects on male and female reproductive organs were observed in a 3-month repeat dose study in cynomolgus monkeys, however, most animals in these studies were not sexually mature.

7.1 Special Populations

7.1.1 Pregnant Women

Based on its mechanism of action, Zynzyz. Zynzyz can cause fetal harm when administered to a pregnant woman. There are no available data on the use of Zynzyz. Zynzyz in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death.

Human IgG4 immunoglobulins (IgG4) are known to cross the placenta; therefore, retifanlimab has the potential to be transmitted from the mother to the developing fetus.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Zynyz is not recommended during pregnancy and in women of childbearing potential not using effective contraception unless the clinical benefit outweighs the potential risk. Women of childbearing potential should use effective contraception during treatment with Zynyz and for at least 4 months after the last dose of Zynyz.

7.1.2 Breastfeeding

It is unknown whether Zynyz is excreted in human milk. Human IgGs are known to be excreted in breast milk; a risk to the breastfeeding newborns/infants cannot be excluded.

Women should be advised not to breastfeed during treatment and for at least 4 months after the last dose of Zynyz.

7.1.3 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

Geriatrics (≥ 65 years of age): No overall differences in efficacy were observed between younger patients and elderly patients. Limited information is available to draw conclusions on any differences in safety between younger and elderly patients. No dose adjustment is needed for patients who are ≥ 65 years of age.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Metastatic or Advanced Merkel cell carcinoma (previously untreated)

PODIUM-201 trial

The safety of Zynzyz was evaluated in 101 patients in the PODIUM-201 trial with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for MCC (see 14 CLINICAL TRIALS). Patients received Zynzyz 500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months. The median duration of exposure was 10.3 months (range: 1 day to 24.8 months), 62.4% of patients received Zynzyz for more than 6 months and 47.5% for more than 1 year. The median number of infusions was 12 (range: 1 dose to 28 doses).

Among the 101 patients, the median age was 71 years (range: 38-90); 76.2% \geq 65 years; 67.3% male; 77.2% White, 21.8% were race unknown or not reported, and 1% were Asian.

Serious treatment-emergent adverse events occurred in 25.7% of patients receiving Zynzyz. Zynzyz, including asthenia (3%), pneumonitis and atrial fibrillation (2% each).

Treatment-emergent adverse events with a fatal outcome occurred in 4% of patients, which were concomitant disease progression of chronic lymphocytic leukemia, asthenia, acute respiratory failure and COVID-19 (1% each).

Permanent discontinuation of Zynzyz due to treatment-emergent adverse events occurred in 20.8% of patients, including infusion-related reaction (2%), colitis, diarrhea, demyelinating polyneuropathy, fatigue, hepatitis, transaminases increased, eosinophilic fasciitis, polyarthritis, hypophysitis, pancreatitis, toxic epidermal necrolysis, and tubulointerstitial nephritis (1% each).

Dosage interruptions due to treatment-emergent adverse events occurred in 40.6% of patients who received Zynzyz, including (\geq 2%) Zynzyz transaminases increased, amylase increased, lipase increased, pyrexia, pneumonitis, rash, and colitis.

The most common (\geq 10%) adverse reactions that occurred in patients receiving Zynzyz were fatigue, pruritus, diarrhea, rash, arthralgia, musculoskeletal pain, COVID-19, constipation, cough, and pyrexia.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials therefore may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Table 3 summarizes adverse reactions that occurred in $\geq 5\%$ patients with metastatic or recurrent locally advanced MCC who received Zynzyz in the POD1UM-201 trial.

Table 3: Adverse Reactions in $\geq 5\%$ of Patients With Metastatic or Recurrent Locally Advanced MCC Who Received Zynzyz in POD1UM-201

| Adverse Reaction | Zynzyz (N = 101) | |
|---|---------------------|--------------------|
| | All Grades n (%) | Grade 3-4 n (%) |
| Blood and lymphatic system disorders | | |
| Anemia ^a | 7 (6.9) | 2 (2) |
| Endocrine disorders | | |
| Hypothyroidism | 8 (7.9) | 0 |
| Hyperthyroidism | 6 (5.9) | 0 |
| Gastrointestinal disorders | | |
| Diarrhea | 19 (18.8) | 0 |
| Constipation | 12 (11.9) | 0 |
| Nausea | 10 (9.9) | 0 |
| Abdominal pain ^b | 6 (5.9) | 0 |
| Dry mouth | 6 (5.9) | 0 |
| Vomiting | 5 (5) | 0 |
| General disorders and administration site conditions | | |
| Fatigue ^c | 31 (30.7) | 1 (1) |
| Pyrexia | 11 (10.9) | 0 |
| Edema ^d | 7 (6.9) | 0 |
| Injury, poisoning and procedural complications | | |
| Infusion related reaction ^e | 4 (4) | 2 (2) |

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Table 3: Adverse Reactions in ≥ 5% of Patients With Metastatic or Recurrent Locally Advanced MCC Who Received Zynzy in PODIUM-201

| Adverse Reaction | Zynzy (N = 101) | |
|--|---------------------|--------------------|
| | All Grades n (%) | Grade 3-4 n (%) |
| Infections and infestations | | |
| COVID-19 | 14 (13.9) | 2 (2) |
| Urinary tract infection | 7 (6.9) | 1 (1) |
| Transaminases increased ^f | 9 (8.9) | 3 (3) |
| Blood creatinine increased | 7 (6.9) | 0 |
| Metabolism and nutrition disorders | | |
| Decreased appetite | 6 (5.9) | 0 |
| Musculoskeletal and connective tissue disorders | | |
| Arthralgia | 17 (16.8) | 1 (1) |
| Musculoskeletal pain ^g | 17 (16.8) | 2 (2) |
| Myalgia | 5 (5) | 0 |
| Nervous system disorders | | |
| Headache | 5 (5) | 0 |
| Psychiatric disorders | | |
| Insomnia | 6 (5.9) | 0 |
| Respiratory, thoracic and mediastinal disorders | | |
| Cough ^h | 11 (10.9) | 0 |
| Dyspnea ⁱ | 6 (5.9) | 0 |
| Pneumonitis ^j | 5 (5) | 2 (2) |
| Skin and subcutaneous skin disorders | | |
| Pruritus | 22 (21.8) | 0 |
| Rash ^k | 18 (17.8) | 2 (2) |
| Erythema | 6 (5.9) | 0 |
| Dry skin | 5 (5) | 0 |

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Table 3: Adverse Reactions in ≥ 5% of Patients With Metastatic or Recurrent Locally Advanced MCC Who Received Zynzy in PODIUM-201

| Adverse Reaction | Zynzy (N = 101) | |
|---------------------------|---------------------|--------------------|
| | All Grades n (%) | Grade 3-4 n (%) |
| Vascular disorders | | |
| Hypertension | 7 (6.9) | 1 (1) |

Graded according to NCI CTCAE v5.0.

a Includes anemia and iron deficiency anemia.

b Includes abdominal pain and abdominal pain upper.

c Includes fatigue and asthenia.

d Includes edema and edema peripheral.

e Includes infusion related reaction and drug hypersensitivity.

f Includes transaminases increased, alanine aminotransferase increased, and aspartate aminotransferase.

g Includes back pain, bone pain, musculoskeletal chest pain, neck pain, and pain in extremity.

h Includes cough and productive cough.

i Includes dyspnea and dyspnea exertional.

j Includes pneumonitis, interstitial lung disease, and organizing pneumonia.

k Includes rash, rash maculo-papular, rash erythematous, rash pruritic, dermatitis, psoriasis, rash papular, dermatitis bullous, and toxic epidermal necrolysis.

Description of selected adverse reactions

The selected adverse reactions described below are based on the safety of retifanlimab in a pooled safety population of 452 patients with advanced solid malignancies, including 107 patients with metastatic or recurrent locally advanced MCC. The management guidelines for these adverse reactions are described in Table 1.

Immune-mediated adverse reactions (see 4 DOSAGE AND ADMINISTRATION, Table 1, and 7 WARNINGS AND PRECAUTIONS)

Immune-mediated pneumonitis

Immune-mediated pneumonitis occurred in 3.1% of patients receiving Zynzy, including 1.3% of patients with Grade 2, 0.9% of patients with Grade 3 and 0.2% of patients with Grade 5. The median time to onset of pneumonitis was 100 days (range: 43-673 days). Pneumonitis led to discontinuation of Zynzy in 0.2% of patients. Among the patients with pneumonitis, 71.4% of patients received systemic corticosteroids. Pneumonitis resolved in 78.6% of patients, with a median time to resolution of 37 days (range: 9-104 days).

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Immune-mediated colitis

Immune-mediated colitis occurred in 2.7% of patients receiving Zynzyz, including 1.1% of patients with Grade 2, 0.4% of patients with Grade 3, and 0.2% of patients with Grade 4. The median time to onset of colitis was 165.5 days (range: 11-749 days). Colitis led to discontinuation of Zynzyz in 0.9% of patients. Among the patients with colitis, 75% received systemic corticosteroids and 8.3% received another immunosuppressant (infliximab). Colitis resolved in 66.7% of patients, with a median time to resolution of 83.5 days (range: 15-675 days).

Immune-mediated nephritis

Immune-mediated nephritis occurred in 2% of patients receiving Zynzyz, including 0.4% of patients with Grade 2, 1.1% of patients with Grade 3, and 0.4% of patients with Grade 4. The median time to onset of nephritis was 176 days (range: 15-515 days). Nephritis led to discontinuation of Zynzyz in 1.1% of patients. Among the patients with nephritis, 66.7% received systemic corticosteroids. Nephritis resolved in 44.4% of patients, with a median time to resolution of 22.5 days (range: 9-136 days).

Immune-mediated hepatitis

Immune-mediated hepatitis occurred in 3.5% of patients receiving Zynzyz, including 0.9% of patients with Grade 2, 2.4% of patients with Grade 3, and 0.2% of patients with Grade 4. The median time to onset of hepatitis was 70.5 days (range: 8-580 days). Hepatitis led to discontinuation of Zynzyz in 1.5% of patients. Among the patients with hepatitis, 81.3% of patients received systemic corticosteroids and 6.3% of patients received another immunosuppressant (mycophenolate mofetil). Hepatitis resolved in 56.3% of patients, with a median time to resolution of 22 days (range: 6-104 days).

Immune-mediated skin reactions

Immune-mediated skin reactions occurred in 9.5% of patients receiving Zynzyz, including 8% of patients with Grade 2, 1.1% of patients with Grade 3, and 0.2% of patients with Grade 4. The median time to onset of skin reactions was 86 days (range: 2-589 days). Skin reactions led to discontinuation of Zynzyz in 0.7% of patients. Among the patients with skin reactions, 32.6% of patients received systemic corticosteroids. Skin reactions resolved in 72.1% of patients, with a median time to resolution of 37 days (range: 3-470 days).

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Immune-mediated endocrinopathies

Hypothyroidism occurred in 10.2% of patients receiving Zyny, including 4.9% of patients with Grade 2. The median time to onset of hypothyroidism was 88 days (range: 1-505 days).

None of the events led to discontinuation of Zyny. Among the patients with hypothyroidism, resolution occurred in 32.6% of patients, with a median time to resolution of 56 days (range: 2-224 days).

Hyperthyroidism occurred in 5.8% of patients receiving Zyny, including 2.7% of patients with Grade 2. The median time to onset of hyperthyroidism was 55.5 days (range: 8-575 days).

None of the events led to discontinuation of Zyny. Among the patients with hyperthyroidism, resolution occurred in 61.5% of patients, with a median time to resolution of 74 days (range: 15-295 days).

Hypophysitis occurred in 0.7% of patients receiving Zyny, including 0.4% of patients with Grade 2 and 0.2% of patients with Grade 3. The median time to onset of hypophysitis was 308 days (range, 266-377 days). Hypophysitis led to discontinuation of Zyny in 0.2% of patients. Hypophysitis resolved in 33.3% of patients, with a time to resolution of 6 days.

Adrenal insufficiency occurred in 0.9% of patients receiving Zyny, including 0.4% of patients with Grade 2 and 0.4% of patients with Grade 3. The median time to onset of adrenal insufficiency was 220.5 days (range: 146-275 days). None of the events led to discontinuation of Zyny. Among the patients with adrenal insufficiency, resolution occurred in 25% of patients, with a time to resolution of 12 days.

Type 1 diabetes mellitus presenting as diabetic ketoacidosis (Grade 3) occurred in 0.2% of patients receiving Zyny. The time to onset of diabetic ketoacidosis was 284 days. The event did not lead to discontinuation of Zyny and resolved with a time to resolution of 6 days.

Infusion-related reactions

Infusion-related reactions occurred in 6.2% of patients, including 2.2% of patients with Grade 2 and 0.4% of patients with Grade 3. Infusion-related reactions led to discontinuation of Zyny in 0.4% of patients.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

8.3 Less Common Clinical Trial Adverse Reactions

The following adverse reactions were reported in < 5% of patients with treatment-naïve metastatic or recurrent locally advanced MCC who received ZYNYZ in the POD1UM-201 trial.

Endocrine disorders: adrenal insufficiency, autoimmune thyroiditis, hypophysitis

Gastrointestinal disorders: colitis, pancreatitis, stomatitis

Hepatobiliary disorders: hepatitis

Infections and infestations: pneumonia

Investigations: blood thyroid stimulating hormone increased

Metabolism and nutrition disorders: diabetic ketoacidosis, hyperglycemia

Musculoskeletal and connective tissue disorders: eosinophilic fasciitis, polyarthritis

Nervous system disorders: demyelinating polyneuropathy, paresthesia, peripheral neuropathy

Renal and urinary disorders: acute kidney injury, tubulointerstitial nephritis

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinical Trial Findings

Table 4 summarizes laboratory abnormalities in patients with metastatic or recurrent locally advanced MCC who received Zynzyz in the POD1UM-201 trial.

Table 4: Laboratory Abnormalities that Worsened from Baseline to Grade 3 or 4 Occurring in ≥ 1% of Patients with Metastatic or Recurrent Locally Advanced MCC Receiving Zynzyz in POD1UM-201

| Laboratory Test | Zynzyz (N = 101) | |
|-----------------------|---------------------|--------------------|
| | All Grades n (%) | Grade 3-4 n (%) |
| Hematology | | |
| Decreased hemoglobin | 42 (41.6) | 1 (1) |
| Decreased lymphocytes | 28 (27.7) | 9 (8.9) |
| Decreased neutrophils | 13 (12.9) | 3 (3) |
| Decreased leukocytes | 11 (10.9) | 1 (1) |

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Table 4: Laboratory Abnormalities that Worsened from Baseline to Grade 3 or 4 Occurring in $\geq 1\%$ of Patients with Metastatic or Recurrent Locally Advanced MCC Receiving Zynzyz in POD1UM-201

| Laboratory Test | Zynzyz (N = 101) | |
|--------------------------------------|---------------------|--------------------|
| | All Grades n (%) | Grade 3-4 n (%) |
| Chemistry | | |
| Increased lipase | 37 (36.6) | 5 (5) |
| Increased aspartate aminotransferase | 26 (25.7) | 3 (3.1) |
| Decreased sodium | 26 (25.7) | 3 (3) |
| Increased alanine aminotransferase | 25 (24.8) | 4 (4.2) |
| Increased amylase | 22 (21.8) | 1 (1) |
| Increased alkaline phosphatase | 22 (21.8) | 2 (2) |
| Increased potassium | 20 (19.8) | 1 (1) |
| Decreased potassium | 15 (14.9) | 2 (2) |
| Decreased calcium | 12 (11.9) | 1 (1) |
| Increased calcium | 10 (9.9) | 1 (1) |

Graded according to NCI CTCAE v5.0.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

No formal pharmacokinetic drug interaction studies have been conducted with Zynyz. Since retifanlimab is cleared from the circulation through catabolism, metabolic drug-drug interactions are not expected.

The use of systemic corticosteroids or immunosuppressants before starting Zynyz, except for physiological doses of systemic corticosteroids (≤ 10 mg/day prednisone or equivalent), should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of Zynyz. However, systemic corticosteroids or other immunosuppressants can be used after starting Zynyz to treat immune-mediated adverse reactions (see 7 WARNINGS AND PRECAUTIONS and Table 1).

Retifanlimab is not expected to be involved in drug-drug interactions involving drug transporters or CYP enzymes.

HIV antiretroviral medications may be substrates, inhibitors, or inducers of the P-glycoprotein and multidrug-resistant protein transporters and the cytochrome P450 (CYP) enzyme system. No clinically important differences in the clearance of retifanlimab were found in a limited number of HIV-positive patients taking antiretroviral medications.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Retifanlimab is an IgG4 monoclonal antibody that binds to PD-1 and blocks its interaction with its ligands PD-L1 and PD-L2. Engagement of PD-1 with its ligands PD-L1 and PD-L2, which are expressed by antigen presenting cells and may be expressed by tumor cells and/or other cells in the tumor microenvironment, results in inhibition of T-cell function such as proliferation, cytokine secretion, and cytotoxic activity. Retifanlimab binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and potentiates T-cell activity.

10.2 Pharmacodynamics

The exposure-response relationship and time course of pharmacodynamic response for safety and effectiveness of retifanlimab have not been fully characterized.

10.3 Pharmacokinetics

The pharmacokinetics of retifanlimab were characterised using a non-compartmental analysis (NCA) with concentration data collected from 97 patients with various cancers who received retifanlimab 500 mg every 4 weeks.

Table 5: Summary of Zynzyz Pharmacokinetic Parameters in Patients With Various Solid Tumors (NCA Analysis)

| | First Dose | | | | | Steady State | | |
|--------|-----------------------------------|--------------------------------|---------------------------------|--|----------------------------|---------------------------|---|---|
| | C_{\max} (mg/L) ^a | T_{\max} (h) ^b | $t_{1/2}$ (day) ^a | AUC_{inf} (mg/L* day) ^a | CL (L/day) ^a | V_z (L) ^a | $C_{\min, ss}$ (mg/L) ^{a,c} | $C_{\max, ss}$ (mg/L) ^{a,c} |
| 500 mg | 192 ± 144 | 1.3 | 15.6 ± 6.68 | 1980 ± 675 | 0.284 ± 0.107 | 5.90 ± 1.99 | 55.4 ± 27.3 | 269 ± 307 |
| Q4W | (175, 37.8%) | (1.0-7.3) | (14.6, 36.7%) | (1870, 35.2%) | (0.267, 35.2%) | (5.61, 33%) | (47.7, 68.8%) | (229, 47.4%) |

Q4W = every 4 weeks; C_{\max} = maximum concentration; T_{\max} = time to maximum concentration; $t_{1/2}$ = terminal half-life; AUC_{inf} = area under the concentration-time curve from time 0 to infinity; CL = clearance; V_z = volume of distribution; $C_{\min, ss}$ = minimum concentration at steady state; $C_{\max, ss}$ = maximum concentrate at steady state.

^a Values presented in the format of mean ± SD (geometric mean, coefficient of variation %)

^b T_{\max} reported as median (range)

^c Concentration data collected from 57 patients with various cancers who received retifanlimab 500 mg every 4 weeks

For the 500 mg every 4 weeks dosing regimen, the accumulation ratio (C_{\max}) was approximately 1.3.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

Absorption

Retifanlimab is administered via the intravenous route and is completely bioavailable.

Distribution:

The geometric mean value for volume of distribution is 5.61 L (coefficient of variation [CV]: 33%).

Metabolism:

The metabolic route of retifanlimab has not been characterized. Retifanlimab is expected to be catabolized through protein degradation processes.

Elimination

Based on a NCA, the elimination half-life of retifanlimab after the first dose is 14.6 days (CV: 36.7%). Clearance parameter of retifanlimab after the first dose was 0.27 L/day (CV: 35.2%).

Special Populations and Conditions

Covariate analysis of the Population Pharmacokinetic model suggests that the following factors have no clinically meaningful effect on the exposure pharmacokinetics of retifanlimab: age (18 to 94 years), sex, body weight (35 to 133 kg), race (White, Black, Asian), albumin level (21 to 54 g/L), ECOG score (0 to 2), tumor burden (sum of the target lesion diameters: 10 to 360 mm), HIV status, renal function (estimated glomerular filtration rate \geq 26 mL/min/1.73 m²), or mild hepatic impairment.

- Hepatic Insufficiency:** The effect of hepatic impairment on the clearance of retifanlimab was evaluated by population pharmacokinetic analyses in patients with mild (n = 78; total bilirubin [TB] > ULN to 1.5 ULN or AST > ULN) hepatic impairment compared to patients with normal (n = 555; TB and AST \leq ULN) hepatic function. No clinically important differences were found in the clearance parameter of retifanlimab. There are limited data in patients with moderate (n = 1; TB between 1.5 and 3.0 times ULN and any AST) hepatic impairment. Retifanlimab has not been studied in patients with severe (TB between 3 and 10 \times ULN and any AST) hepatic impairment.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

- **Renal Insufficiency:** The effect of renal impairment on the clearance of retifanlimab was evaluated by population pharmacokinetic analyses in patients with mild (n = 277) or moderate (n = 142) renal impairment (eGFR between 89 and 30 mL/min/1.73 m²; n = 419) compared to patients with normal renal function (eGFR ≥ 90 mL/min/1.73 m²; n = 200). No clinically important differences were found in the clearance parameter of retifanlimab. There are limited data in patients with severe renal impairment (n = 4, lowest eGFR 26.0 mL/min/1.73 m²). Retifanlimab has not been studied in patients with end-stage renal disease.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

**Clinical
pharmacology**

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

11 STORAGE, STABILITY AND DISPOSAL

Store at 2°C to 8°C.

Store in the original carton in order to protect from light.

Do not freeze.

For storage conditions after reconstitution or dilution of the medicinal product, see 4 DOSAGE AND ADMINISTRATION, 4.3 Reconstitution.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Indications

Contraindications

Dosage and
administration

Overdosage

Dosage forms,
strengths, composition
and packaging

Warnings and
precautions

Adverse reactions

Drug interactions

Clinical
pharmacology

**Storage, stability
and disposal**

Pharmaceutical
information

Clinical trials

Microbiology

Non-clinical
Toxicology

Patient medication
information

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Retifanlimab for injection

Chemical name: Recombinant anti-human PD-1 monoclonal antibody

Molecular mass: 148 kDa

Structural formula: Retifanlimab is a humanized, hinge-stabilized, IgG4κ monoclonal antibody (mAb). It contains a human IgG4 Fc region that has been mutated to greatly reduce or eliminate hinge inter-chain disulfide instability. Retifanlimab is comprised of two identical light chain polypeptides and two identical heavy chain polypeptides that are covalently linked by disulfide bonds.

Physicochemical properties: Clear to slightly opalescent, colorless to pale yellow solution, free of visible particles.

Product Characteristics: Retifanlimab is a heterogeneous protein that has the intended primary structure, post-translational modifications, and other characteristics of a recombinant IgG4 derived from Chinese Hamster Ovary (CHO) cells.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Metastatic and Advanced Merkel Cell Carcinoma (previously untreated)

Trial Design and Study Demographics

Table 6: Summary of Patient Demographics for POD1UM-201

| Study # | Study Design | Dosage, Route of Administration, and Duration | Study Subjects (n) | Mean Age (Range) | Sex |
|------------|---|---|--------------------|--------------------------|------------------------------|
| POD1UM-201 | Open-label, single-arm, multiregional study | 500 mg every 4 weeks until disease progression or unacceptable toxicity for a maximum of 2 year | 101 | 71.1 years (38-90 years) | Male: 67.3% Female: 32.7% |

The efficacy of ZYNYZ (retifanlimab for injection) was studied in the POD1UM-201 study, an open-label, single-arm, multiregional study that enrolled 101 patients with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for their advanced disease. Patients with active autoimmune disease or a medical condition that required immunosuppression, severe hepatic or renal impairment, evidence of interstitial lung disease, clinically significant cardiac disease, history of organ transplant, known central nervous system metastases or ECOG performance score (PS) ≥ 2 were ineligible. Patients who were HIV-positive, with an undetectable viral load, a CD4+ count ≥ 300 cells/microliter and receiving antiretroviral therapy were eligible.

Patients received Zynzyz 500 mg every 4 weeks until disease progression or unacceptable toxicity for a maximum of 2 years. Tumor response assessment was performed every 8 weeks for the first year of therapy and 12 weeks thereafter. The primary efficacy outcome measure was confirmed objective response rate (ORR) as assessed by an independent central review committee according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Duration of response was a key secondary outcome.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

In the 101 treated patients, the median age was 71.0 years (range: 38-90 years) with 38.6% age 75 or older; 67.3% of patients were male; 77.2% of patients were Caucasian, 1.0% were Asian and 21.8% were race unknown or not reported; and the ECOG performance status was 0 (73.3%) or 1 (26.7%). Thirty- seven percent (36.6%) of patients were reported to have had prior radiotherapy and 68.3% had prior surgery. Ninety percent (90.1%) of patients had metastatic disease. One HIV-positive patient was enrolled. The majority of tumor samples were positive (72.3%) for Merkel cell polyomavirus while 19.8% were negative, 3.0% equivocal, 1.0% not evaluable and 4.0% missing. Tumor samples were tested for PD-L1 expression retrospectively based on a PD-L1 IHC assay using clone 22C3. PD-L1 status by the combined positive score (CPS) $\geq 1\%$ was in 82.2% of patients and $< 1\%$ in 11.9% of patients; PD-L1 status by the tumor proportion score (TPS) $\geq 1\%$ was in 18.8% of patients and $< 1\%$ in 75.2% of patients; 5.9% of patients had no tissue submitted or tissue not evaluable.

Study Results

Efficacy results are summarized in Table 7. The median duration of follow-up was 17.6 months (range: 1.1 - 38.7 months).

Table 7: Results of PODIUM-201 in Patients with Metastatic or Recurrent Locally Advanced MCC

| Endpoint | ZYNYZ (N = 101) |
|----------------------------------|----------------------|
| Objective response rate (95% CI) | 55.5% (43.3%, 65.5%) |
| Complete response, n (%) | 17 (16.8) |
| Partial response, n (%) | 37 (36.6) |

CI = confidence interval

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

The median duration of response among the 54 patients who responded was 25.3 months (95% CI: 14.2 months, not estimable).

In an exploratory subgroup analysis, the ORR was 16.7% and 57.8% in the subgroups of PD-L1 CPS expression <1% and $\geq 1\%$, respectively; ORR was 46.1% and 84.2% in the subgroups of PD-L1 TPS expression <1% and $\geq 1\%$, respectively.

14.3 Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity with Zynzyz. The presence of anti-drug antibodies (ADAs) was tested in 106 patients with MCC who received Zynzyz. The incidence of retifanlimab treatment-emergent ADAs was 2.8% (3/106) using a bridging enzyme-linked immunosorbent assay following a median exposure time of 312 days. Neutralizing antibodies were detected in 2 of 3 patients with treatment-emergent ADAs. The effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of retifanlimab products is unknown.

Immunogenicity data are highly dependent on the sensitivity and specificity of the assay as well as other factors. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies across studies, including retifanlimab in other studies, other retifanlimab products or other products, may be misleading.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

15 MICROBIOLOGY

No microbiological information is required for this drug product.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Patient medication information

16 NON-CLINICAL TOXICOLOGY

General Toxicology

No significant findings were observed in toxicological studies conducted in monkeys treated with retifanlimab for up to 13 weeks duration at higher exposures compared to the clinical exposure in humans at the recommended dose of 500 mg retifanlimab every 4 weeks.

Carcinogenicity

No studies have been performed to assess the carcinogenic potential of retifanlimab.

Genotoxicity

No studies have been performed to assess the genotoxic potential of retifanlimab.

Reproductive and Developmental Toxicology

Animal reproduction and development toxicity studies have not been conducted with retifanlimab. A central function of the PD1/PDL1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PDL1 signaling has been shown to disrupt maternal tolerance to the fetus resulting in an increased fetal loss. As such, potential risks of administering retifanlimab during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD1/PDL1 signaling in the offspring of these mice; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on the mechanism of action for retifanlimab, fetal exposure may increase the risk of developing immune-mediated disorders or altering the normal immune response.

Special Toxicology Studies: PD-1 deficiency was associated with enhanced inflammatory responses, increased severity of infections and reduced survival in some animal models. Compared to wild-type mice, PD-1 knockout mice infected with *M. tuberculosis* had enhanced inflammatory responses, increased bacterial proliferation and decreased survival. Decreased survival has also been observed in PD-1 knockout mice infected with LCMV.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE



Retifanlimab for injection

Read this carefully before you start taking **Zynzyz** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Zynzyz**.

What is Zynzyz used for?

Zynzyz is a prescription medicine used in adults to treat Merkel cell carcinoma, a rare type of skin cancer. It is given when the cancer has spread or returned and cannot be treated with surgery or radiation.

How does Zynzyz work?

Zynzyz works by helping your immune system fight your cancer.

What are the ingredients in Zynzyz?

Medicinal ingredients: retifanlimab

Non-medicinal ingredients: Glacial acetic acid, polysorbate 80, sodium acetate, sucrose, and water for injection.

Zynzyz comes in the following dosage forms:

Zynzyz comes in a 20 mL glass vial containing 500 mg of retifanlimab.

Do not use Zynzyz if:

- You are allergic to retifanlimab or any of the other ingredients in this medicine. Talk to your health care professional if you are not sure.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Zynzyz. Talk about any health conditions or problems you may have, including if you have:

- an autoimmune disease (a condition where the body's immune system attacks its own cells)

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

- lung or breathing problems
- liver problems
- kidney problems
- diabetes
- solid organ transplant or a bone marrow (stem cell) transplant that used donor stem cells (allogeneic hematopoietic stem cell transplantation)
- any other medical conditions

Other warnings you should know about:

Pregnancy:

- You must not be given Zynyz if you are pregnant unless your doctor specifically recommends it.
- Zynyz can cause harmful effects or death to your unborn baby.
- If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before you are given this medicine.
- Women who could become pregnant must use effective contraception during treatment and for at least 4 months after the last Zynyz dose.

Breastfeeding:

- Do not breastfeed during treatment and for at least 4 months after your last dose of Zynyz.
- It is not known if Zynyz passes into breast milk. A risk to the breastfeeding newborns/infants cannot be excluded.
- Ask your doctor for advice if you are breastfeeding.

Children and adolescents:

- Zynyz should not be used in children and adolescents below 18 years of age.

Driving and using machines

- Zynyz may have an influence on the ability to drive and use machines. If you feel tired, do not drive or use machines until you feel better.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.

- This applies in particular to medicines that suppress your immune system, such as corticosteroids, which may disrupt

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

the effect of Zynyz. Once you are treated with Zynyz, your doctor may prescribe corticosteroids to reduce side effects that you may have during treatment. This will not impact the effect of the medicine.

How to take Zynyz:

- Zynyz will be given to you in a hospital or clinic, supervised by a doctor experienced in cancer treatment.
- Your doctor will give you Zynyz as a drip into a vein (intravenous infusion) which will last about 30 minutes.

Usual dose:

- The recommended dose of Zynyz is 500 mg every 4 weeks.
- Your doctor will decide how many treatments you need.

Overdose:

If you think you, or a person you are caring for, have taken too much Zynyz, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

- It is very important that you do not miss a dose of this medicine.
- Contact your doctor or hospital immediately to reschedule your appointment.

What are possible side effects from using Zynyz?

These are not all the possible side effects you may have when taking Zynyz. If you experience any side effects not listed here, tell your healthcare professional.

These side effects may happen at any time during treatment, or even after your treatment has ended. You may get more than one side effect at the same time, involving any organs and tissues. Sometimes the side effect(s) could be severe or life-threatening and rarely, fatal. If you experience any symptoms that are severe enough to interfere with daily activities, notify your healthcare professional immediately or proceed to the emergency department.

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

Very common (may affect more than 1 in 10 people):

- diarrhea
- nausea
- constipation
- rash
- itching of the skin (*pruritus*)
- joint pain (*arthralgia*)
- tiredness (*fatigue*)
- fever (*pyrexia*)
- muscle and bone pain (*musculoskeletal pain*)
- cough

Common (may affect up to 1 in 10 people):

- decrease in the number of red blood cells (*anemia*)
- thyroid gland problems (*hypothyroidism, hyperthyroidism, autoimmune thyroiditis*)
- decreased secretion of hormones produced by the adrenal glands (*adrenal insufficiency*)
- decreased appetite
- abnormal sensation such as tingling or numbness of the hands or feet (*paraesthesia*)
- increased blood level of liver enzymes, including alanine aminotransferase and aspartate aminotransferase
- increased blood levels of creatinine
- increased blood levels of thyroid stimulating hormone
- infusion-related reactions that can cause symptoms such as chills, shaking or fever, itching or rash, flushing or swollen face, being short of breath or wheezing, feeling dizzy or nausea.
- inflammation of the liver (*hepatitis*)
- inflammation of the lungs (*pneumonitis*)
- build up of fluid in the body or extremities causing swelling (*edema*)
- urinary tract infection
- high blood pressure (*hypertension*)
- abdominal pain
- dry mouth

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

- trouble sleeping (*insomnia*)
- redness of the skin (*erythema*)
- shortness of breath (*dyspnea*)
- vomiting
- headache
- muscle pain (*myalgia*)
- dry skin
- inflammation of the mouth or mouth sores (*stomatitis*)
- lung infection (*pneumonia*)
- inflammation of the nerves causing tingling, numbness, weakness or burning pain of the arms or legs (*peripheral neuropathy*)

Uncommon (may affect up to 1 in 100 people):

- inflammation of the pancreas (*pancreatitis*)
- diabetic ketoacidosis that can cause symptoms such as difficulty thinking clearly, sleepiness, stomach pain, fast and deep breathing, breath that smells sweet or fruity, sweet or metallic taste in the mouth or a different odor to urine or sweat
- inflammation of the eyes (*uveitis*)
- inflammation of the tissue between the muscle and skin which may cause skin swelling (*eosinophilic fasciitis*)
- joint inflammation (*polyarthritis*)
- damage to the nerves and nerve coverings (*demyelinating polyneuropathy*)
- inflammation of the kidneys (*tubulointerstitial nephritis*)

| Serious Side Effects and What To Do About Them | | | |
|--|--------------------------------------|--------------|---|
| Symptom / Effect | Talk to Your Healthcare Professional | | Stop Taking Drug and Get Immediate Medical Help |
| | Only if Severe | In All Cases | |
| COMMON (may affect up to 1 in 10 people) | | | |
| Lung inflammation (<i>pneumonitis</i>); breathing difficulties, chest pain, or new or worsening cough. | | X | |

| |
|--|
| Indications |
| Contraindications |
| Dosage and administration |
| Overdosage |
| Dosage forms, strengths, composition and packaging |
| Warnings and precautions |
| Adverse reactions |
| Drug interactions |
| Clinical pharmacology |
| Storage, stability and disposal |
| Pharmaceutical information |
| Clinical trials |
| Microbiology |
| Non-clinical Toxicology |
| Patient medication information |

| Serious Side Effects and What To Do About Them | | | |
|--|--------------------------------------|--------------|---|
| Symptom / Effect | Talk to Your Healthcare Professional | | Stop Taking Drug and Get Immediate Medical Help |
| | Only if Severe | In All Cases | |
| Bowel inflammation (<i>colitis</i>): frequent diarrhea often with blood and/or mucus, more bowel movements than usual, stools that are bloody, black or tarry and severe abdominal pain or tenderness. | | X | |
| Sudden kidney damage (<i>acute kidney injury</i>): decreased volume of urine, foamy urine, passing blood or traces of blood in the urine that may change its color, swollen ankles, or loss of appetite. | | X | |
| Infusion-related reaction: chills, shaking or fever, itching or rash, flushing or swollen face, being short of breath or wheezing, feeling dizzy or feel like passing out and back or neck pain, nausea, vomiting, or abdominal pain. | | X | |
| Inflammation of the pituitary gland in the base of the brain (<i>hypophysitis</i>): headache, nausea, vomiting, increased thirst, vision changes | | X | |
| UNCOMMON (may affect up to 1 in 100 people) | | | |
| Liver inflammation (<i>hepatitis</i>): persistent nausea or vomiting, loss of appetite, pain on the right side of your stomach, eye and/or skin yellowing, drowsiness, darkcolored urine, bleeding, or bruising more easily than normal. | | X | |
| Acid in the blood produced from diabetes (<i>diabetic ketoacidosis</i>) | | X | |
| Pinched nerve caused by damage to the root of the nerve(s) in the spine (<i>radiculopathy</i>) | | X | |
| Inflammation of the pancreas (<i>pancreatitis</i>) | | X | |

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/healthcanada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects.

The Canada Vigilance Program does not provide medical advice.

Storage:

It is unlikely that you will be asked to store ZynyZ yourself. It will be stored in the hospital or clinic where it is given to you.

Store in a refrigerator (2°C-8°C). Do not freeze. Store in the original package in order to protect from light. Keep out of reach and sight of children.

If you want more information about ZynyZ:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drugproducts/drug-product-database.html>, the manufacturer's website: www.incytebiosciences.ca, or by calling 1-833-309-2759.

This leaflet was prepared by Incyte Corporation, Wilmington, Delaware 19803 USA.

Last Revised FEB 06, 2025

Indications

Contraindications

Dosage and administration

Overdosage

Dosage forms, strengths, composition and packaging

Warnings and precautions

Adverse reactions

Drug interactions

Clinical pharmacology

Storage, stability and disposal

Pharmaceutical information

Clinical trials

Microbiology

Non-clinical Toxicology